Details

Autor(en) / Beteiligte

• Ibáñez-Costa, Alejandro
• Perez-Sanchez, Carlos
• Patiño-Trives, Alejandra María
• Luque-Tevar, Maria
• Font, Pilar
• Arias de la Rosa, Ivan
• Roman-Rodriguez, Cristobal
• Abalos-Aguilera, Mª Carmen
• Conde, Carmen
• Gonzalez, Antonio
• Pedraza-Arevalo, Sergio
• Del Rio-Moreno, Mercedes
• Blazquez-Encinas, Ricardo
• Segui, Pedro
• Calvo, Jerusalem
• Ortega Castro, Rafaela
• Escudero-Contreras, Alejandro
• Barbarroja, Nuria
• Aguirre, Mª Angeles
• Castaño, Justo P
• Luque, Raul M
• Collantes-Estevez, Eduardo
• Lopez-Pedrera, Chary

Titel

Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy

Ist Teil von

• Annals of the rheumatic diseases, 2022-01, Vol.81 (1), p.56-67

Ort / Verlag

England

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• To characterise splicing machinery (SM) alterations in leucocytes of patients with rheumatoid arthritis (RA), and to assess its influence on their clinical profile and therapeutic response. Leucocyte subtypes from 129 patients with RA and 29 healthy donors (HD) were purified, and 45 selected SM elements (SME) were evaluated by quantitative PCR-array based on microfluidic technology (Fluidigm). Modulation by anti-tumour necrosis factor (TNF) therapy and underlying regulatory mechanisms were assessed. An altered expression of several SME was found in RA leucocytes. Eight elements ( and ) were equally altered in all leucocytes subtypes. Logistic regressions revealed that this signature might: discriminate RA and HD, and anti-citrullinated protein antibodies (ACPAs) positivity; classify high-disease activity (disease activity score-28 (DAS28) >5.1); recognise radiological involvement; and identify patients showing atheroma plaques. Furthermore, this signature was altered in RA synovial fluid and ankle joints of K/BxN-arthritic mice. An available RNA-seq data set enabled to validate data and identified distinctive splicing events and splicing variants among patients with RA expressing high and low SME levels. 3 and 6 months anti-TNF therapy reversed their expression in parallel to the reduction of the inflammatory profile. In vitro, ACPAs modulated SME, at least partially, by Fc Receptor (FcR)-dependent mechanisms. Key inflammatory cytokines further altered SME. Lastly, induced overexpression and -overexpression reversed inflammation in lymphocytes, NETosis in neutrophils and adhesion in RA monocytes and influenced activity of RA synovial fibroblasts. Overall, we have characterised for the first time a signature comprising eight dysregulated SME in RA leucocytes from both peripheral blood and synovial fluid, linked to disease pathophysiology, modulated by ACPAs and reversed by anti-TNF therapy.